submit to the journals

Interstitial Lung Disease Journal Articles, Videos And Insights

Interstitial Lung Disease:FEATURED Articles

flipper_slider

Interstitial Lung Disease: INSIGHTS

The touchRESPIRATORY website provides a selection of resources to inform clinicians and patients about the latest developments in the field. The following are quick, non peer-reviewed, opinion-based updates addressing current trends and opinion on the most recent advances in the area of respiratory medicine:

Insight
Highlights from the ERS International Congress 2018 – Focus on Idiopathic Pulmonary Fibrosis Katrina Mountfort, Senior Medical Writer, Touch Medical Media, UK
Shanker Krishna, Account Director, Touch Medical Media, UK
Insights into idiopathic pulmonary fibrosis research presented at European Respiratory Society Congress, Paris, September 15-19, 2018.
Insight
Highlights from the ATS International Congress 2018— Focus on IPF Alex Lowe, Senior Medical Writer, Touch Medical Media, UK
Shanker Krishna, Account Director and Advisory Editor, Touch Medical Media, UK
Insights into IPF research presented at American Thoracic Society International Congress, San Diego, CA, US, May 18–23, 2018.
Insight
Highlights from the ERS International Congress 2017: focus on idiopathic pulmonary fibrosis Katrina Mountfort, Senior Medical Writer, Touch Medical Media, UK
Matthew Goodwin, Respiratory Business Unit Director, Touch Medical Media, UK

Interstitial Lung Disease:FEATURED VIDEOS

Editor's choice

Dr. Aryeh Fischer discusses highlights of a session held at the 2015 ATS annual conference which focused on several topics related to the management of ILD and related diseases. In addition, he discusses the announcement of a new disease classification, 'interstitial pneumonia with autoimmune features', developed by an international task force under the umbrella of American Thoracic Society and the European Respiratory Society.
Yohannes Ghebre (Baylor College of Medicine, Houston, TX, US) discusses the rationale and clinical evidence to date for using proton pump inhibitors (PPIs) to treat idiopathic pulmonary fibrosis (IPF). Questions 1. What are the limitations of the currently approved drugs, pirfenidone and nintedanib, in idiopathic pulmonary fibrosis (IPF)? (0:11) 2. What is the rationale for using proton pump inhibitors (PPIs) to treat IPF? (1:08) 3. What clinical evidence exists for the use of PPIs in IPF? (2:06) 4. What (if any) are the potential safety issues in using PPIs to treat patients with IPF? (2:55) 5. What further studies are needed? (3:26) Speaker disclosure: Yohannes Ghebre is an inventor on a patent, owned by Stanford University, that protects the use of proton pump inhibitors (PPIs) for the treatment of idiopathic pulmonary fibrosis (IPF). Filmed at the American Thoracic Society (ATS) International Conference 2018, San Diego, CA, US, May 2018.

Interstitial Lung Disease:Latest Videos

Video List based on Category on Node Page

Latest Videos

Mary E Strek (University of Chicago, Chicago, IL, US) brings us up to speed on important aspects of autoimmune lung diseases. Questions 1. How prevalent are autoimmune lung diseases? (0:10) 2. What are the major autoimmune causes of interstitial lung diseases? (0:36) 3. What are the major...
Jonathan H Chung (University of Chicago, Chicago, IL, US) shares his expert insights on radiology imaging of interstitial lung diseases. Questions 1. What are the most radiologic characteristics of the different types of interstitial lung disease (ILD)? (0:10) 2. What further investigations...
Simon Walsh (King’s College NHS Foundation Trust, King's College London, London, UK) discusses the background and findings of his late-breaking presentation entitled: A Deep Learning Algorithm for Classifying Fibrotic Lung Disease on High Resolution Computed Tomography. Questions 1. What...
Yohannes Ghebre (Baylor College of Medicine, Houston, TX, US) discusses the rationale and clinical evidence to date for using proton pump inhibitors (PPIs) to treat idiopathic pulmonary fibrosis (IPF). Questions 1. What are the limitations of the currently approved drugs, pirfenidone and...
The FDA has fast-tracked Ofev and Esbriet as approved medications for IPF. Together with stem cell therapy, we're closer to finding a cure for IPF.
Dr. Aryeh Fischer discusses highlights of a session held at the 2015 ATS annual conference which focused on several topics related to the management of ILD and related diseases. In addition, he discusses the announcement of a new disease classification, 'interstitial pneumonia with autoimmune...

LATEST TWEETS

Conference Highlights